Perlmutter Cancer Center

The purpose of the trial is to assess the safety (side effects) and efficacy (benefits) of the investigational drug relacorilant (also referred to as CORT125134) together with the chemotherapy drug, nab-paclitaxel, in patients with metastatic pancreatic cancer. We want to know if the addition of relacorilant to nab-paclitaxel controls the cancer and how tumors respond to the combination of relacorilant and nab-paclitaxel. Relacorilant is an investigational drug in this study because it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States.